Abraxane Randomized Trial Needed For Adjuvant Breast Cancer, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC votes in favor of Abraxis conducting an additional clinical trial to extend Abraxane’s indication from metastatic breast cancer into the adjuvant setting during a Sept. 7 meeting.
You may also be interested in...
Abraxis Cited Again for cGMP Violations At Illinois Facility
Firm tells “The Pink Sheet” DAILY it has taken “aggressive actions” in response to issues mentioned in a late 2006 FDA warning letter.
Abraxis Cited Again for cGMP Violations At Illinois Facility
Firm tells “The Pink Sheet” DAILY it has taken “aggressive actions” in response to issues mentioned in a late 2006 FDA warning letter.
Oncology Panel To Determine Whether Abraxane Needs Randomized Trial In Adjuvant Breast Cancer
The committee will consider if previous studies of Bristol’s Taxol, which has the same active ingredient as Abraxane, are sufficient to support approval via the 505(b)(2) pathway.